William Blair downgraded Inari Medical (NARI) to Market Perform from Outperform after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical price target raised at Piper after agreeing to be acquired
- Inari Medical downgraded to Hold from Buy at Canaccord
- Inari Medical downgraded to Hold from Buy at Deutsche Bank
- Inari Medical downgraded to Neutral from Outperform at Baird
- Closing Bell Movers: Inari adds 21% after confirmed Stryker buyout